Amedisys INC Form 4 insider transactions

Allyson Guidroz, Chief Accounting Officer of Amedisys Inc., reports acquisition and disposal of common stock and restricted stock units (RSUs).

Nick Muscato, Chief Strategy Officer of Amedisys Inc., reports the acquisition of 5,832 restricted stock units and the disposition of shares to cover tax obligations.

Chief Compliance Officer Denise M. Bohnert of Amedisys Inc. reports the acquisition of 5,832 restricted stock units (RSUs) and the disposal of shares for tax withholding.

Jennifer G. Griffin, Chief Legal Officer of Amedisys Inc., reports the acquisition of 5,832 shares of common stock through restricted stock units (RSUs) and a change in indirect ownership via a 401(k) plan.

Scott Ginn, EVP, CFO & COO of Amedisys Inc., reports acquiring 17,495 shares of common stock through time-based RSUs and disposing of 1,795 shares to cover tax obligations.

Amedisys CEO Richard M. Ashworth received 58,316 time-based Restricted Stock Units (RSUs) on February 16, 2025, according to a Form 4 filing with the SEC.

Amedisys CEO Richard Ashworth disposed of 11,079 shares of common stock to cover tax obligations related to the accelerated vesting of restricted stock units.

Amedisys Inc.'s Chief Legal Officer, Jennifer G. Griffin, reported a transaction involving the withholding of 3,507 common stock shares to cover taxes upon the accelerated vesting of restricted stock units.

Chief Strategy Officer Nick Muscato reports acquiring 10,421 shares of Amedisys Inc. common stock through restricted stock units (RSUs).

Allyson Guidroz, Chief Accounting Officer of Amedisys Inc., reports the acquisition of 2,179 shares of common stock through restricted stock units (RSUs).

Nick Muscato, Chief Strategy Officer of Amedisys Inc., reports the disposition of shares to cover tax obligations.

Allyson Guidroz, Chief Accounting Officer of Amedisys Inc., reports the disposal of 102 shares of common stock to cover tax obligations.

Scott G. Ginn, EVP, CFO & COO of Amedisys Inc., reported the disposal of 2,391 shares of common stock to cover tax obligations.

Allyson Guidroz, Chief Accounting Officer of Amedisys Inc., reports a transaction involving common stock on June 1, 2024.

Director Ivanetta Davis Samuels received 1,678 restricted stock units from Amedisys Inc. on May 3, 2024, which will vest on May 3, 2025, contingent upon continued service on the Board of Directors.

Allyson Guidroz, Chief Accounting Officer of Amedisys Inc., reports the acquisition of restricted stock units and disposition of shares to cover tax liabilities.

Director Molly Joel Coye received 1,678 restricted stock units from Amedisys Inc. on May 3, 2024, which will vest on May 3, 2025, contingent upon continued service on the board.

Director Vickie L Capps received 1,678 restricted stock units from Amedisys Inc. on May 3, 2024, which will vest on May 3, 2025, contingent upon continued service on the Board of Directors.

Director Teresa L. Kline received 1,678 restricted stock units from Amedisys Inc. on May 3, 2024, which will vest on May 3, 2025, contingent upon continued service on the Board of Directors.

Director Bruce D. Perkins acquired 1,678 restricted stock units in Amedisys Inc. on May 3, 2024.

Director Paul B. K. Kusserow of Amedisys Inc. was awarded 1,678 restricted stock units that will vest on May 3, 2025, contingent upon continued service on the Board of Directors.

Director Julie D. Klapstein reports the acquisition of 1,678 restricted stock units in Amedisys Inc.

Director Jeffrey A. Rideout received 1,678 restricted stock units from Amedisys Inc. on May 3, 2024, which will vest on May 3, 2025, contingent upon continued service on the Board of Directors.